Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

Adoptive cellular therapy using chimeric antigen receptor T-cell (CART) therapy is currently being evaluated in patients with relapsed / refractory multiple myeloma (MM). The majority of CAR-T cell programs now being tested in clinical trials are targeting B-cell maturation antigen. Several recent p...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Haematologica
Главные авторы: Moreau, Philippe, Sonneveld, Pieter, Boccadoro, Mario, Cook, Gordon, Mateos, Ma Victoria, Nahi, Hareth, Goldschmidt, Hartmut, Dimopoulos, Meletios A., Lucio, Paulo, Bladé, Joan, Delforge, Michel, Hajek, Roman, Ludwig, Heinz, Facon, Thierry, Miguel, Jesus F. San, Einsele, Hermann
Формат: Artigo
Язык:Inglês
Опубликовано: Ferrata Storti Foundation 2019
Предметы:
Guideline Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6959167/
https://ncbi.nlm.nih.gov/pubmed/31439675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.224204
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы